356 related articles for article (PubMed ID: 31819163)
21. Role of Proteomics in the Development of Personalized Medicine.
Jain KK
Adv Protein Chem Struct Biol; 2016; 102():41-52. PubMed ID: 26827601
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenomics and individualized medicine: translating science into practice.
Crews KR; Hicks JK; Pui CH; Relling MV; Evans WE
Clin Pharmacol Ther; 2012 Oct; 92(4):467-75. PubMed ID: 22948889
[TBL] [Abstract][Full Text] [Related]
23. Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer.
Morganti S; Tarantino P; Ferraro E; D'Amico P; Duso BA; Curigliano G
Adv Exp Med Biol; 2019; 1168():9-30. PubMed ID: 31713162
[TBL] [Abstract][Full Text] [Related]
24. The Ubiquitous Pharmacogenomics consortium: making effective treatment optimization accessible to every European citizen.
Manson LE; van der Wouden CH; Swen JJ; Guchelaar HJ
Pharmacogenomics; 2017 Jul; 18(11):1041-1045. PubMed ID: 28685652
[No Abstract] [Full Text] [Related]
25. Pharmacometabonomics in humans: a new tool for personalized medicine.
Everett JR
Pharmacogenomics; 2015; 16(7):737-54. PubMed ID: 25929853
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomics in pediatrics: personalized medicine showing eminent promise.
Mele C; Goldschmidt K
J Pediatr Nurs; 2014; 29(4):378-82. PubMed ID: 24880100
[No Abstract] [Full Text] [Related]
27. Clinical Applications of Personalized Medicine: A New Paradigm and Challenge.
Di Sanzo M; Cipolloni L; Borro M; La Russa R; Santurro A; Scopetti M; Simmaco M; Frati P
Curr Pharm Biotechnol; 2017; 18(3):194-203. PubMed ID: 28240172
[TBL] [Abstract][Full Text] [Related]
28. Personalized Medicine and Adverse Drug Reactions: The Experience of An Italian Teaching Hospital.
La Russa R; Fineschi V; Di Sanzo M; Gatto V; Santurro A; Martini G; Scopetti M; Frati P
Curr Pharm Biotechnol; 2017; 18(3):274-281. PubMed ID: 28176638
[TBL] [Abstract][Full Text] [Related]
29. The emerging era of pharmacogenomics: current successes, future potential, and challenges.
Lee JW; Aminkeng F; Bhavsar AP; Shaw K; Carleton BC; Hayden MR; Ross CJ
Clin Genet; 2014 Jul; 86(1):21-8. PubMed ID: 24684508
[TBL] [Abstract][Full Text] [Related]
30. 4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation.
Sipeky C; Llerena A; Manolopoulos VG; Pearson E; Mlakar V; Gozzo L; Simmaco M; Marchetti P; Re MD; Stankovic S; Meyer U; Cascorbi I; Ingelman-Sundberg M; Suarez-Kurtz G; Marc J; Katsila T; Paulmichl M; Nofziger C; Ansari M; Drago F; van Schaik RH
Pharmacogenomics; 2019 Oct; 20(15):1063-1069. PubMed ID: 31588876
[TBL] [Abstract][Full Text] [Related]
31. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing.
Lauschke VM; Ingelman-Sundberg M
Eur J Pharm Sci; 2019 Mar; 130():65-77. PubMed ID: 30684656
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenomics in the clinic.
Relling MV; Evans WE
Nature; 2015 Oct; 526(7573):343-50. PubMed ID: 26469045
[TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetics of Clopidogrel Therapy and Neurointerventional Procedures: We Need Precision Data for Precision Medicine.
Rakicevic L; Nestorovic A
Clin Pharmacol Ther; 2019 Mar; 105(3):547-549. PubMed ID: 29920652
[TBL] [Abstract][Full Text] [Related]
34. Catalyzing clinical implementation of pharmacogenomics and personalized medicine interventions in Africa.
Mathuba B; Koromina M; Mitropoulou C; Patrinos GP
Pharmacogenomics; 2021 Jan; 22(2):115-122. PubMed ID: 33353428
[TBL] [Abstract][Full Text] [Related]
35. Pharmacogenomics to achieve precision medicine.
Empey PE
Am J Health Syst Pharm; 2016 Dec; 73(23):1906-1907. PubMed ID: 27784662
[No Abstract] [Full Text] [Related]
36. The future of research into genetics and the precision dosing of tacrolimus: what do we need to know?
Zhu J; Pasternak AL; Crona DJ
Pharmacogenomics; 2020 Oct; 21(15):1061-1064. PubMed ID: 32896220
[No Abstract] [Full Text] [Related]
37. Pharmacogenomics at the center of precision medicine: challenges and perspective in an era of Big Data.
Primorac D; Bach-Rojecky L; Vađunec D; Juginović A; Žunić K; Matišić V; Skelin A; Arsov B; Boban L; Erceg D; Ivkošić IE; Molnar V; Ćatić J; Mikula I; Boban L; Primorac L; Esquivel B; Donaldson M
Pharmacogenomics; 2020 Jan; 21(2):141-156. PubMed ID: 31950879
[TBL] [Abstract][Full Text] [Related]
38. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review).
Vizirianakis IS; Mystridis GA; Avgoustakis K; Fatouros DG; Spanakis M
Oncol Rep; 2016 Apr; 35(4):1891-904. PubMed ID: 26781205
[TBL] [Abstract][Full Text] [Related]
39. Personalized Medicine in the Paediatric Population: The Balance Between Pharmacogenetic Progress and Bioethics.
Schiavone S; Neri M; Pomara C; Riezzo I; Trabace L; Turillazzi E
Curr Pharm Biotechnol; 2017; 18(3):253-262. PubMed ID: 28176639
[TBL] [Abstract][Full Text] [Related]
40. Personalized medicine in psoriasis: concept and applications.
Al-Hoqail IA
Curr Vasc Pharmacol; 2010 May; 8(3):432-6. PubMed ID: 19758113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
